Brave Asset Management’s Edwards Lifesciences EW Stock Holding History

Brave Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,200	Closed	-$48K	–	202
2016 Q3	$48K	Buy	+1,200	New	+$45.2K	0.03%	220
2016 Q2	–	Sell	-1,200	Closed	-$35K	–	409
2016 Q1	$35K	Hold	1,200	–	–	0.02%	250
2015 Q4	$32K	Buy	+1,200	New	+$31.2K	0.02%	259
2015 Q3	–	Sell	-1,200	Closed	-$28K	–	429
2015 Q2	$28K	Hold	1,200	–	–	0.02%	282
2015 Q1	$28K	Hold	1,200	–	–	0.02%	281
2014 Q4	$25K	Sell	1,200 -4,800	-80%	-$96.4K	0.02%	289
2014 Q3	$102K	Hold	6,000	–	–	0.08%	167
2014 Q2	$86K	Hold	6,000	–	–	0.06%	182
2014 Q1	$74K	Hold	6,000	–	–	0.06%	183
2013 Q4	$66K	Buy	+6,000	New	+$67.6K	0.05%	193

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Brave Asset Management's EW Position: Q4 2016 in Review

Brave Asset Management sold out of Edwards Lifesciences (EW) in Q4 2016, closing a stake of 1,200 shares — an estimated $48K sold.

Brave Asset Management first reported a position in EW in Q4 2013 and held it in 10 quarters. The position peaked at $102K in Q3 2014. 686 funds tracked by Wall St. Rank hold EW as of Q4 2016.

Brave Asset Management reported no remaining Edwards Lifesciences position as of Q4 2016 after selling out during the quarter.
Brave Asset Management sold 1,200 Edwards Lifesciences shares in Q4 2016, an estimated $48K.
Brave Asset Management first reported a position in Edwards Lifesciences in Q4 2013 and held it in 10 quarters.
Brave Asset Management's Edwards Lifesciences position peaked at $102K in Q3 2014.
686 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2016.

Based on Brave Asset Management's 13F filing for Q4 2016, filed 27 Jan 2017.